ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,229.99
-1.19%
Dow Jones
42,063.36
0.09%
Gold vs US Dollar
2,622.30
1.35%
Brent Oil
74.135
-0.25%
Bitcoin
63,202.24
0.40%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. RAPT Therapeutics Inc (RAPT)

  7. RAPT Therapeutics Inc (RAPT) News

RAPT Therapeutics (RAPT)

RAPT Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:RAPT
DateTimeSourceHeadlineSymbolCompany
08/08/202413:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RAPTRAPT Therapeutics Inc
08/08/202413:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
08/08/202413:00GlobeNewswire Inc.RAPT Therapeutics Reports Second Quarter 2024 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
19/07/202422:24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
23/05/202423:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAPTRAPT Therapeutics Inc
23/05/202423:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAPTRAPT Therapeutics Inc
23/05/202423:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAPTRAPT Therapeutics Inc
23/05/202423:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAPTRAPT Therapeutics Inc
23/05/202421:49Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
09/05/202413:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RAPTRAPT Therapeutics Inc
09/05/202413:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
09/05/202413:00GlobeNewswire Inc.RAPT Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
09/04/202417:00GlobeNewswire Inc.RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer PatientsNASDAQ:RAPTRAPT Therapeutics Inc
07/03/202421:15Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RAPTRAPT Therapeutics Inc
07/03/202413:08Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:RAPTRAPT Therapeutics Inc
07/03/202413:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
07/03/202413:00GlobeNewswire Inc.RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
05/03/202421:30GlobeNewswire Inc.RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual MeetingNASDAQ:RAPTRAPT Therapeutics Inc
22/02/202422:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
20/02/202421:29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
20/02/202412:30GlobeNewswire Inc.RAPT Therapeutics Announces Clinical Hold on Studies Evaluating ZelnecirnonNASDAQ:RAPTRAPT Therapeutics Inc
14/02/202413:52Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RAPTRAPT Therapeutics Inc
13/02/202413:00GlobeNewswire Inc.RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical OperationsNASDAQ:RAPTRAPT Therapeutics Inc
31/01/202413:00GlobeNewswire Inc.RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:RAPTRAPT Therapeutics Inc
02/01/202413:00GlobeNewswire Inc.RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:RAPTRAPT Therapeutics Inc
27/11/202313:00GlobeNewswire Inc.RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in AllergyNASDAQ:RAPTRAPT Therapeutics Inc
13/11/202313:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RAPTRAPT Therapeutics Inc
13/11/202313:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
13/11/202313:00GlobeNewswire Inc.RAPT Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
03/11/202316:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:RAPT

Your Recent History

NASDAQ
ROP
Roper Technologies
BIT
P1ZPV2
NLBNPIT1ZPV2 20241220 200
USOTC
LMDWF
LumiraDx (CE)
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved